Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE9.7600
- TODAY'S CHANGE (%)-0.0400 (-0.4082%)
- Bid / Lots8.4000/ 3
- Ask / Lots11.0000/ 1
- Open / Previous Close9.7600 / 9.8000
- Day Range
- 52 Week Range
- Volume356,822
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 1816 | 9.735 |
| 09:34 ET | 417 | 9.735 |
| 09:36 ET | 100 | 9.735 |
| 09:38 ET | 400 | 9.735 |
| 09:39 ET | 200 | 9.78 |
| 09:41 ET | 200 | 9.735 |
| 09:43 ET | 1000 | 9.745 |
| 09:45 ET | 2340 | 9.86 |
| 09:48 ET | 500 | 9.815 |
| 09:50 ET | 200 | 9.815 |
| 09:52 ET | 302 | 9.84 |
| 09:54 ET | 100 | 9.815 |
| 09:56 ET | 313 | 9.81 |
| 09:57 ET | 200 | 9.795 |
| 09:59 ET | 800 | 9.795 |
| 10:01 ET | 1834 | 9.71 |
| 10:03 ET | 1085 | 9.75 |
| 10:06 ET | 500 | 9.755 |
| 10:08 ET | 3620 | 9.775 |
| 10:10 ET | 200 | 9.775 |
| 10:12 ET | 200 | 9.78 |
| 10:14 ET | 4113 | 9.72 |
| 10:15 ET | 4200 | 9.77 |
| 10:17 ET | 4399 | 9.79 |
| 10:19 ET | 1200 | 9.76 |
| 10:21 ET | 912 | 9.79 |
| 10:24 ET | 649 | 9.8 |
| 10:26 ET | 352 | 9.8 |
| 10:28 ET | 3040 | 9.84 |
| 10:30 ET | 2673 | 9.855 |
| 10:32 ET | 1100 | 9.86 |
| 10:33 ET | 1104 | 9.88 |
| 10:35 ET | 1098 | 9.84 |
| 10:37 ET | 791 | 9.845 |
| 10:39 ET | 600 | 9.845 |
| 10:42 ET | 1300 | 9.77 |
| 10:44 ET | 1100 | 9.79 |
| 10:46 ET | 1019 | 9.79 |
| 10:48 ET | 939 | 9.79 |
| 10:50 ET | 600 | 9.77 |
| 10:51 ET | 1323 | 9.75 |
| 10:53 ET | 1419 | 9.7125 |
| 10:55 ET | 800 | 9.66 |
| 10:57 ET | 772 | 9.685 |
| 11:00 ET | 1000 | 9.685 |
| 11:02 ET | 5358 | 9.64 |
| 11:04 ET | 569 | 9.655 |
| 11:06 ET | 200 | 9.655 |
| 11:08 ET | 1403 | 9.625 |
| 11:09 ET | 1300 | 9.6 |
| 11:11 ET | 500 | 9.6 |
| 11:13 ET | 3396 | 9.66 |
| 11:15 ET | 1150 | 9.65 |
| 11:18 ET | 400 | 9.64 |
| 11:20 ET | 400 | 9.64 |
| 11:22 ET | 5782 | 9.715 |
| 11:24 ET | 1997 | 9.695 |
| 11:26 ET | 100 | 9.705 |
| 11:27 ET | 369 | 9.705 |
| 11:29 ET | 323 | 9.7 |
| 11:31 ET | 1647 | 9.635 |
| 11:33 ET | 739 | 9.635 |
| 11:36 ET | 200 | 9.635 |
| 11:38 ET | 1752 | 9.61 |
| 11:40 ET | 600 | 9.65 |
| 11:42 ET | 4569 | 9.595 |
| 11:44 ET | 670 | 9.59 |
| 11:45 ET | 300 | 9.5964 |
| 11:47 ET | 1219 | 9.58 |
| 11:49 ET | 1204 | 9.595 |
| 11:51 ET | 1771 | 9.61 |
| 11:54 ET | 2601 | 9.565 |
| 11:56 ET | 400 | 9.57 |
| 11:58 ET | 623 | 9.575 |
| 12:00 ET | 300 | 9.57 |
| 12:02 ET | 6536 | 9.57 |
| 12:03 ET | 2646 | 9.6 |
| 12:05 ET | 100 | 9.62 |
| 12:07 ET | 339 | 9.62 |
| 12:09 ET | 1544 | 9.62 |
| 12:12 ET | 3800 | 9.68 |
| 12:14 ET | 345 | 9.645 |
| 12:16 ET | 200 | 9.65 |
| 12:18 ET | 3606 | 9.685 |
| 12:20 ET | 400 | 9.7 |
| 12:21 ET | 600 | 9.6867 |
| 12:23 ET | 1400 | 9.69 |
| 12:25 ET | 6219 | 9.71 |
| 12:27 ET | 3562 | 9.7 |
| 12:30 ET | 3200 | 9.7 |
| 12:32 ET | 100 | 9.7 |
| 12:34 ET | 1548 | 9.7 |
| 12:36 ET | 300 | 9.7 |
| 12:38 ET | 5934 | 9.7 |
| 12:39 ET | 6958 | 9.68 |
| 12:41 ET | 1100 | 9.65 |
| 12:43 ET | 3678 | 9.67 |
| 12:45 ET | 20538 | 9.7 |
| 12:48 ET | 10489 | 9.7 |
| 12:50 ET | 2540 | 9.71 |
| 12:52 ET | 6304 | 9.75 |
| 12:54 ET | 4475 | 9.77 |
| 12:56 ET | 4255 | 9.74 |
| 12:57 ET | 8131 | 9.725 |
| 12:59 ET | 63845 | 9.76 |
Jun 20, 2024
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 1.6B | -6.3x | --- |
Kura Oncology Inc | 1.5B | -9.2x | --- |
Keros Therapeutics Inc | 1.5B | -8.2x | --- |
Akero Therapeutics Inc | 1.5B | -6.8x | --- |
Morphic Holding Inc | 1.6B | -9.1x | --- |
Soleno Therapeutics Inc | 1.5B | -15.7x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
